Literature DB >> 29346790

Multivisceral Resection for Locally Invasive Colorectal Liver Metastases: Outcomes of a Matched Cohort Analysis.

Fiona Hand1, Rebeca Sanabria Mateos1, Michael Durand1, David Fennelly2, Ray McDermott2, Donal Maguire1, Justin Geoghegan1, Des Winter3, Emir Hoti1.   

Abstract

Local invasion of adjacent viscera by colorectal liver metastases (CRLM) is no longer considered an absolute contraindication to curative hepatic resection. A growing number of observational analyses have illustrated the feasibility of such resections; however, the evidence base is at best heterogeneous with a lack of evidence comparing similar patient groups. We aimed to evaluate the outcomes of hepatectomy for CRLM when combined with other viscera and compare to a matched cohort of isolated hepatic resections.
METHODS: From 2005 to 2015, 523 patients underwent hepatic resection for CRLM at our institution, 19 of whom underwent hepatectomy with extrahepatic resection. A 3: 1 matched cohort analysis was performed between those who underwent isolated hepatectomy (control group) and those who underwent hepatectomy with extrahepatic resection (combined group). Clinicopathological data were reviewed along with 30-day postoperative morbidity and mortality. Furthermore, overall survival for the multivisceral cohort was compared to all other isolated hepatectomies over the same time period.
RESULTS: Nineteen patients underwent liver resection accompanied by either/or diaphragmatic resection (n = 13), major vein resection and reconstruction (n = 5), and visceral resection (n = 3). Maximum tumor size was significantly larger in the combined group (60.58 vs. 15.34 mm p < 0.0001). Postoperative morbidity was similar in both groups (p = 0.41). Following multivisceral resection, 1-, 3- and 5-year survival rates were 75, 56.6, and 25.7% respectively. Overall survival showed no significant difference between combined and control groups (p = 0.78). Similarly, when compared to the total cohort of isolated liver resections (n = 504), no significant difference in overall mortality was noted.
CONCLUSION: In patients presenting with concomitant CRLM and extrahepatic extension where R0 margins can be achieved, this present study supports the rationale to proceed to -surgery with comparable morbidity and mortality rates to -isolated hepatectomy.
© 2018 S. Karger AG, Basel.

Entities:  

Keywords:  Colorectal cancer; Diaphragm; Hepatic resection; Inferior vena cava; Liver metastases; Multivisceral resection

Mesh:

Year:  2018        PMID: 29346790     DOI: 10.1159/000485198

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  4 in total

1.  Current trends in vena cava reconstructive techniques with major liver resection: a systematic review.

Authors:  Maria Baimas-George; Christoph Tschuor; Michael Watson; Jesse Sulzer; Patrick Salibi; David Iannitti; John B Martinie; Erin Baker; Pierre-Alain Clavien; Dionisios Vrochides
Journal:  Langenbecks Arch Surg       Date:  2020-09-26       Impact factor: 3.445

2.  Direct inpatient costs and influencing factors for patients with rectal cancer with low anterior resection: a retrospective observational study at a three-tertiary hospital in Beijing, China.

Authors:  Zhishui Chen; Jiahua Leng; Guangying Gao; Lianhai Zhang; Yang Yang
Journal:  BMJ Open       Date:  2018-12-18       Impact factor: 2.692

Review 3.  The impact of multivisceral liver resection on short- and long-term outcomes of patients with colorectal liver metastasis: A systematic review and meta-analysis.

Authors:  Sérgio Silveira Júnior; Francisco Tustumi; Daniel de Paiva Magalhães; Vagner Birk Jeismann; Gilton Marques Fonseca; Jaime Arthur Pirola Kruger; Fabricio Ferreira Coelho; Paulo Herman
Journal:  Clinics (Sao Paulo)       Date:  2022-09-16       Impact factor: 2.898

4.  Laparoscopic liver resection with simultaneous diaphragm resection.

Authors:  Airazat M Kazaryan; Davit L Aghayan; Åsmund A Fretland; Vasiliy I Semikov; Alexander M Shulutko; Bjørn Edwin
Journal:  Ann Transl Med       Date:  2020-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.